Randomized Phase 3 Trial of Adjuvant Androgen Deprivation in Combination With High-Dose Conformal Radiation Therapy in Intermediate- and High-Risk Localized Prostate Cancer

Zapatero, A.; Guerrero, A.; Maldonado, J; Alvarez, A.; Segundo, Carmen González San; Rodriguez, M. Cabeza; Macías, Víctor; Pedro-Olive, A.; Casas, Francesc; Boladeras, A.; Vidales, C. Martín de; Torre, Maria Vazquez de La

doi:10.1016/j.ijrobp.2014.06.018

Cited by 7 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Zapatero et al, reported on a study of men with intermediate and high risk localized prostate cancer ( n = 362), treated with RT + long term ADT versus RT + short term ADT, and found that long term ADT was superior in 5-year biochemical disease free survival, metastasis free survival, and OS [ 135 ].…”

Section: Introductionmentioning

confidence: 99%

The biology and treatment of oligometastatic cancer

2015

View full text Add to dashboard Cite

Clinical reports of limited and treatable cancer metastases, a disease state that exists in a transitional zone between localized and widespread systemic disease, were noted on occasion historically and are now termed oligometastasis. The ramification of a diagnosis of oligometastasis is a change in treatment paradigm, i.e. if the primary cancer site (if still present) is controlled, or resected, and the metastatic sites are ablated (surgically or with radiation), a prolonged disease-free interval, and perhaps even cure, may be achieved. Contemporary molecular diagnostics are edging closer to being able to determine where an individual metastatic deposit is within the continuum of malignancy. Preclinical models are on the outset of laying the groundwork for understanding the oligometastatic state. Meanwhile, in the clinic, patients are increasingly being designated as having oligometastatic disease and being treated owing to improved diagnostic imaging, novel treatment options with the potential to provide either direct or bridging therapy, and progressively broad definitions of oligometastasis.

show abstract

Section: Introductionmentioning

confidence: 99%

The biology and treatment of oligometastatic cancer

2015

View full text Add to dashboard Cite

show abstract

“…For high-risk patients, a prolonged ADT duration of 2-3 years seems to be superior to short-term ADT of 4-6 months [5,6]. This has been confirmed in the high-dose radiotherapy era by the preliminary results of the DART 01/05 trial [38]; …”

Section: Discussionmentioning

confidence: 78%

Consensus and differences in primary radiotherapy for localized and locally advanced prostate cancer in Switzerland

et al. 2015

View full text Add to dashboard Cite

show abstract

“…After 5 years of follow up patients on long term hormonal therapy had statistically signifi cant bett er biochemical free survival, overall survival and metastases free survival (86 vs. 95%, 89 vs. 94% and 85 vs. 93%, respectively). No signifi cant difference in acute and late toxicity was observed between groups (8). In conclusion, benefi t of longterm hormonal treatment still exists, regardless of higher radiation dose applied on prostate.…”

Section: Radiotherapy Vs Combined Modality Approach: Hormonal Therapmentioning

confidence: 74%

Optimal treatment of patients with high-risk prostate cancer

Antunac

2019

lib oncol

View full text Add to dashboard Cite

Treatment options in subset of patients with high-risk prostate cancer are various: radical prostatectomy, hormonal therapy, radiation therapy, combined modality approach, addition of chemotherapy. Based on randomised trials data, optimal approach would consist of radical radiotherapy and long term hormonal therapy. If technically possible high dose radiotherapy, hypofractionation, image guided radiotherapy, simultaneous integrated boost on dominant intraprostatic lesion and HDR brachytherapy boost should be used as well.

show abstract

Randomized Phase 3 Trial of Adjuvant Androgen Deprivation in Combination With High-Dose Conformal Radiation Therapy in Intermediate- and High-Risk Localized Prostate Cancer

Cited by 7 publications

References 0 publications

The biology and treatment of oligometastatic cancer

The biology and treatment of oligometastatic cancer

Consensus and differences in primary radiotherapy for localized and locally advanced prostate cancer in Switzerland

Optimal treatment of patients with high-risk prostate cancer

Contact Info

Product

Resources

About